Sugi Predict

Sugi Predict / Compounds / SCHEMBL940146

SCHEMBL940146

SCHEMBL940146

O=C(O)c1cccc(-c2nn[nH]n2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GP6 Q9HCN6 1/20 0.65
▸ MAPT P10636 2/20 0.58
▸ IDO1 P14902 1/20 0.58
▸ ALDH1A1 P00352 1/20 0.57
▸ KMO O15229 1/20 0.53
▸ AKR1C4 P17516 1/20 0.53
▸ AKR1C3 P42330 1/20 0.53
▸ XDH P47989 3/20 0.51
▸ NPC1 O15118 1/20 0.50
▸ CLK1 P49759 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ CD74 P04233 1/20 0.50
▸ MIF P14174 1/20 0.50
▸ PTGDR2 Q9Y5Y4 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ MAP2K4 P45985 1/20 0.50
▸ MAPKAPK3 Q16644 1/20 0.50
▸ MAPK6 Q16659 1/20 0.50
▸ HPGDS O60760 1/20 0.50
▸ CSNK2A1 P68400 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4367955 0.85 MAPT (0.69) GP6MAPTIDO1ALDH1A1XDH
SCHEMBL30004856 0.85 PFKFB3 (0.60) GP6MAPTIDO1ALDH1A1XDH
SCHEMBL2856871 0.85 PFKFB3 (0.60) GP6MAPTIDO1ALDH1A1XDH
SCHEMBL12203131 0.82 XDH (0.53) GP6MAPTIDO1ALDH1A1XDH
SCHEMBL4261812 0.81 MAPT (0.60) GP6MAPTIDO1ALDH1A1XDH
SCHEMBL12203132 0.80 ADH5 (0.63) GP6XDHNPC1RAB9A
SCHEMBL31734205 0.80 KMO (0.67) ALDH1A1KMONPC1RAB9ACD74
SCHEMBL8783974 0.80 ALDH1A1 (0.51) GP6ALDH1A1HPGDSPOLBL3MBTL1
SCHEMBL29471993 0.79 XDH (0.60) GP6MAPTALDH1A1XDHNPC1
SCHEMBL1249470 0.79 XDH (0.69) XDHNPC1RAB9AHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059469-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS AKT INHIBITORS ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 — — US disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 — — US disclosed
EP-3782997-A1 FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES Galapagos N.V. (BE) 2021-02-24 — — EP disclosed
US-20160361295-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2016-12-15 — — US disclosed
US-20160015685-A1 FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2016-01-21 — — US disclosed
US-9139599-B1 2-periodic metal-organic frameworks (MOFs) as supermolecular building layers (SBLs) for making targeted 3-periodic MOFs UNIVERSITY OF SOUTH FLORIDA (US) 2015-09-22 — — US disclosed
US-20150164912-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2015-06-18 — — US disclosed
US-8933109-B2 Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors AMURA LIMITED (GB) 2015-01-13 — — US disclosed
US-20140038944-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2014-02-06 — — US disclosed
US-8389737-B2 Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors AMURA THERAPEUTICS LIMITED (GB) 2013-03-05 — — US disclosed
EP-2297162-B1 COMPOUNDS AMURA THERAPEUTICS LTD (GB) 2012-08-15 — — EP disclosed
EP-2283022-B1 FURO [3, 2-B]PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2012-07-18 — — EP disclosed
US-8008290-B2 Compounds AMURA THERAPEUTICS LIMITED (GB) 2011-08-30 — — US disclosed
EP-2297162-A1 COMPOUNDS Amura Therapeutics Limited (GB) 2011-03-23 — — EP disclosed
EP-2283022-A1 FURO Ý3, 2-B¨PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS Amura Therapeutics Limited (GB) 2011-02-16 — — EP disclosed
US-20110009385-A1 COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2011-01-13 — — US disclosed
US-20110009386-A1 FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2011-01-13 — — US disclosed
WO-2009112826-A1 FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2009-09-17 — — WO disclosed
WO-2009112839-A1 COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2009-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009385-A1 COMPOUNDS CTSK, CTSS, MMP9 GP6 280/4885MAPT 3024/4885IDO1 3761/4885
US-20160015685-A1 FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK GP6 694/4885MAPT 3942/4885IDO1 1374/4885
US-20160361295-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK GP6 535/4885MAPT 4162/4885IDO1 1613/4885
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC3 GP6 4469/4885MAPT 522/4885IDO1 545/4885
US-20150164912-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK GP6 535/4885MAPT 4162/4885IDO1 1613/4885
US-20140038944-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK GP6 535/4885MAPT 4162/4885IDO1 1613/4885
US-20110009386-A1 FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS CTSS, CTSL, CTSK GP6 694/4885MAPT 3942/4885IDO1 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.